Kyorin Pharmaceutical Co Ltd - Product Pipeline Review - 2016

Published: Dec, 2016 | Pages: 66 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Kyorin Pharmaceutical Co Ltd - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Kyorin Pharmaceutical Co Ltd - Product Pipeline Review - 2016', provides an overview of the Kyorin Pharmaceutical Co Ltd's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Kyorin Pharmaceutical Co Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Kyorin Pharmaceutical Co Ltd
- The report provides overview of Kyorin Pharmaceutical Co Ltd including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Kyorin Pharmaceutical Co Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Kyorin Pharmaceutical Co Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Kyorin Pharmaceutical Co Ltd's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Kyorin Pharmaceutical Co Ltd
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Kyorin Pharmaceutical Co Ltd's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Kyorin Pharmaceutical Co Ltd Snapshot 7
Kyorin Pharmaceutical Co Ltd Overview 7
Key Facts 7
Kyorin Pharmaceutical Co Ltd - Research and Development Overview 8
Key Therapeutic Areas 8
Kyorin Pharmaceutical Co Ltd - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Pipeline Products - Out-Licensed Products 15
Out-Licensed Products/Combination Treatment Modalities 16
Kyorin Pharmaceutical Co Ltd - Pipeline Products Glance 17
Kyorin Pharmaceutical Co Ltd - Late Stage Pipeline Products 17
Phase III Products/Combination Treatment Modalities 17
Kyorin Pharmaceutical Co Ltd - Clinical Stage Pipeline Products 18
Phase II Products/Combination Treatment Modalities 18
Phase I Products/Combination Treatment Modalities 19
Kyorin Pharmaceutical Co Ltd - Early Stage Pipeline Products 20
Preclinical Products/Combination Treatment Modalities 20
Discovery Products/Combination Treatment Modalities 21
Kyorin Pharmaceutical Co Ltd - Drug Profiles 22
AX-10479 - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
ibudilast - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
KCA-1490 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
KRP-109 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
KRP-203 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
KRPAM-1977X - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
KRPAM-1977Y - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
MN-002 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
MTG-201 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
neramexane mesylate - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Small Molecule to Inhibit PDE4 for Inflammation - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
tipelukast - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
vibegron - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
Kyorin Pharmaceutical Co Ltd - Pipeline Analysis 54
Kyorin Pharmaceutical Co Ltd - Pipeline Products by Target 54
Kyorin Pharmaceutical Co Ltd - Pipeline Products by Route of Administration 56
Kyorin Pharmaceutical Co Ltd - Pipeline Products by Molecule Type 57
Kyorin Pharmaceutical Co Ltd - Pipeline Products by Mechanism of Action 58
Kyorin Pharmaceutical Co Ltd - Dormant Projects 60
Kyorin Pharmaceutical Co Ltd - Discontinued Pipeline Products 61
Discontinued Pipeline Product Profiles 61
KEA-0477 61
KRP-104 61
KRP-105 61
KRP-110 61
KRP-203 61
MK-0767 62
ranirestat 62
tipelukast 62
Kyorin Pharmaceutical Co Ltd - Locations And Subsidiaries 63
Head Office 63
Other Locations & Subsidiaries 63
Appendix 65
Methodology 65
Coverage 65
Secondary Research 65
Primary Research 65
Expert Panel Validation 65
Contact Us 65
Disclaimer 66

List of Tables

Kyorin Pharmaceutical Co Ltd, Key Facts 7
Kyorin Pharmaceutical Co Ltd - Pipeline by Indication, 2016 9
Kyorin Pharmaceutical Co Ltd - Pipeline by Stage of Development, 2016 11
Kyorin Pharmaceutical Co Ltd - Monotherapy Products in Pipeline, 2016 12
Kyorin Pharmaceutical Co Ltd - Partnered Products in Pipeline, 2016 13
Kyorin Pharmaceutical Co Ltd - Partnered Products/ Combination Treatment Modalities, 2016 14
Kyorin Pharmaceutical Co Ltd - Out-Licensed Products in Pipeline, 2016 15
Kyorin Pharmaceutical Co Ltd - Out-Licensed Products/ Combination Treatment Modalities, 2016 16
Kyorin Pharmaceutical Co Ltd - Phase III, 2016 17
Kyorin Pharmaceutical Co Ltd - Phase II, 2016 18
Kyorin Pharmaceutical Co Ltd - Phase I, 2016 19
Kyorin Pharmaceutical Co Ltd - Preclinical, 2016 20
Kyorin Pharmaceutical Co Ltd - Discovery, 2016 21
Kyorin Pharmaceutical Co Ltd - Pipeline by Target, 2016 55
Kyorin Pharmaceutical Co Ltd - Pipeline by Route of Administration, 2016 56
Kyorin Pharmaceutical Co Ltd - Pipeline by Molecule Type, 2016 57
Kyorin Pharmaceutical Co Ltd - Pipeline Products by Mechanism of Action, 2016 59
Kyorin Pharmaceutical Co Ltd - Dormant Developmental Projects,2016 60
Kyorin Pharmaceutical Co Ltd - Discontinued Pipeline Products, 2016 61
Kyorin Pharmaceutical Co Ltd, Other Locations 63
Kyorin Pharmaceutical Co Ltd, Subsidiaries 64